MedTrace Logo

Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia

NCT02096510 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-06-07

No results posted yet for this study

Summary

The aim of this study is to compare the effects of tablet treatment, circadian and combined circadian and ultradian subcutaneous hydrocortisone infusion on steroid metabolism and tissue responses to therapy.

Conditions

  • Addison Disease
  • Adrenal Hyperplasia Congenital

Interventions

DRUG

Solu-Cortef

administration by pump for minimum 2 weeks

DRUG

Cortef

tablet treatment 2 ro 3 times per day for 14 days

Sponsors & Collaborators

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Katerina Simunkova, MD, PhD · Universtity of Bergen

  • Kristian Løvås, MD, PhD · Helse Bergen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-27
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02096510 on ClinicalTrials.gov